Molecular pathogenesis of human hepatocellular carcinoma
- PMID: 12149612
- DOI: 10.1038/ng0802-339
Molecular pathogenesis of human hepatocellular carcinoma
Abstract
Hepatocarcinogenesis is a slow process during which genomic changes progressively alter the hepatocellular phenotype to produce cellular intermediates that evolve into hepatocellular carcinoma. During the long preneoplastic stage, in which the liver is often the site of chronic hepatitis, cirrhosis, or both, hepatocyte cycling is accelerated by upregulation of mitogenic pathways, in part through epigenetic mechanisms. This leads to the production of monoclonal populations of aberrant and dysplastic hepatocytes that have telomere erosion and telomerase re-expression, sometimes microsatellite instability, and occasionally structural aberrations in genes and chromosomes. Development of dysplastic hepatocytes in foci and nodules and emergence of hepatocellular carcinoma are associated with the accumulation of irreversible structural alterations in genes and chromosomes, but the genomic basis of the malignant phenotype is heterogeneous. The malignant hepatocyte phenotype may be produced by the disruption of a number of genes that function in different regulatory pathways, producing several molecular variants of hepatocellular carcinoma. New strategies should enable these variants to be characterized.
Similar articles
-
Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats.Eur J Cancer Prev. 2007 Aug;16(4):363-71. doi: 10.1097/01.cej.0000236254.01608.33. Eur J Cancer Prev. 2007. PMID: 17554210
-
Genetic mechanisms of hepatocarcinogenesis.Oncogene. 2002 Apr 11;21(16):2593-604. doi: 10.1038/sj.onc.1205434. Oncogene. 2002. PMID: 11971194 Review.
-
Pathways and gene expression profiles in hepatocellular carcinoma.Minerva Gastroenterol Dietol. 2012 Mar;58(1):35-48. Minerva Gastroenterol Dietol. 2012. PMID: 22419003 Review.
-
Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver.Hepatology. 1998 Jul;28(1):86-9. doi: 10.1002/hep.510280113. Hepatology. 1998. PMID: 9657100
-
Preneoplastic lesions in human hepatocarcinogenesis.Liver Int. 2005 Feb;25(1):16-27. doi: 10.1111/j.1478-3231.2005.01016.x. Liver Int. 2005. PMID: 15698394 Review.
Cited by
-
Systems biology approaches to decoding the genome of liver cancer.Cancer Res Treat. 2011 Dec;43(4):205-11. doi: 10.4143/crt.2011.43.4.205. Epub 2011 Dec 27. Cancer Res Treat. 2011. PMID: 22247704 Free PMC article.
-
Ergosterol peroxide activates Foxo3-mediated cell death signaling by inhibiting AKT and c-Myc in human hepatocellular carcinoma cells.Oncotarget. 2016 Jun 7;7(23):33948-59. doi: 10.18632/oncotarget.8608. Oncotarget. 2016. PMID: 27058618 Free PMC article.
-
Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells.PLoS One. 2013;8(1):e54595. doi: 10.1371/journal.pone.0054595. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23355882 Free PMC article.
-
Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.Hepatology. 2016 Sep;64(3):828-42. doi: 10.1002/hep.28684. Epub 2016 Jul 15. Hepatology. 2016. PMID: 27311882 Free PMC article.
-
IL-22 in hepatocyte's survival of Pakistani patients with end stage liver disease: an insight into IL 22 mediated hepato-regenerative pathway.Mol Biol Rep. 2019 Feb;46(1):1127-1138. doi: 10.1007/s11033-018-04573-x. Epub 2019 Jan 2. Mol Biol Rep. 2019. PMID: 30603953
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases